

RESEARCH

Open Access

# Structural basis for the inhibition of HIV-1 Nef by a high-affinity binding single-domain antibody

Sebastian Lülf<sup>1,2</sup>, Julie Matz<sup>3,4,5</sup>, Marie-Christine Rouyez<sup>3,4,5</sup>, Annika Järviluoma<sup>6</sup>, Kalle Saksela<sup>6</sup>, Serge Benichou<sup>3,4,5</sup> and Matthias Geyer<sup>1,2\*</sup>

## Abstract

**Background:** The HIV-1 Nef protein is essential for AIDS pathogenesis by its interaction with host cell surface receptors and signaling factors. Despite its critical role as a virulence factor Nef is not targeted by current antiviral strategies.

**Results:** We have determined the crystal structure of the complex formed by a camelid single-domain antibody fragment, termed sdAb19, bound to HIV-1 Nef together with a stabilizing SH3 domain. sdAb19 forms a stoichiometric 1:1 complex with Nef and binds to a conformationally conserved surface at the C-terminus of Nef that overlaps with functionally important interaction sites involved in Nef-induced perturbations of signaling and trafficking pathways. The antibody fragment binds Nef with low nanomolar affinity, which could be attenuated to micromolar affinity range by site-directed mutagenesis of key interaction residues in sdAb19. Fusion of the SH3 domain to sdAb19, termed Neffin, leads to a significantly increased affinity for Nef and formation of a stoichiometric 2:2 Nef–Neffin complex. The 19 kDa Neffin protein inhibits all functions of Nef as CD4 and MHC-I downregulation, association with Pak2, and the increase in virus infectivity and replication.

**Conclusions:** Together, sdAb19 and Neffin thus represent efficient tools for the rational development of antiviral strategies against HIV-1 Nef.

**Keywords:** HIV-1 Nef, Single-domain antibody, Crystal structure, Neffin

## Background

The human immunodeficiency virus (HIV) is a persistent pathogen that caused an estimated 1.6 million people deaths in 2012 [1]. Of the fifteen proteins encoded by the HIV genome, the three viral enzymes, protease, integrase and reverse transcriptase are indispensable for the production of viral progeny. These enzymes are core targets of highly active anti-retroviral therapy (HAART) together with proteins mediating virus entry [2,3]. HAART allowed considerable success in reducing viral loads beyond detection levels and elongating patient life expectancy, but the current therapy is unable to clear the virus due to the persistence of latent reservoirs [4]. Advances for a successful eradication strategy showed that HAART in combination

with targeted cytotoxic therapy was able to profoundly deplete productively infected cells of viral RNA [5]. In addition, many broad and potent donor-derived antibodies were uncovered in recent years, suggesting they could be valuable additions to anti-HIV-1 therapies [6]. Yet, the rapid emergence of drug resistant mutants and the increased worldwide spread of treatment resistant HIV-1 variants pose increasing problems to effective treatment of HIV-infected patients. One strategy to improve this situation is the exploitation of additional drug targets that could be added to the current regiment. Ideally, such targets comprise viral factors, since interference with host cell factors may compromise physiological functions or even viability of host cells.

Besides the structural proteins, HIV-1 encodes four accessory proteins to facilitate immune evasion and optimize conditions for virus replication [7]. The accessory *nef* gene encodes a 24–35 kDa protein that is found in all primate lentiviruses and is critical for the full pathogenic potential of these viruses [8]. Nef affects membrane

\* Correspondence: [matthias.geyer@caesar.de](mailto:matthias.geyer@caesar.de)

<sup>1</sup>Center of Advanced European Studies and Research, Group Physical Biochemistry, Bonn, Germany

<sup>2</sup>Department of Physical Biochemistry, Max Planck Institute of Molecular Physiology, Dortmund, Germany

Full list of author information is available at the end of the article

trafficking in infected cells, e.g. by modulating the expression of surface receptors such as CD4, CD8, CD28, MHC-I and MHC-II, DC-SIGN and chemokine receptors in HIV-1 target cells [9]. In addition, Nef also affects signal transduction through interaction with cellular kinases like Pak2 and Hck to modulate signaling pathways in infected cells [9,10]. To achieve this multitude of activities, Nef has evolved as a versatile adaptor for protein interactions that lacks intrinsic enzymatic activity. The structure of HIV-1 Nef is characterized by its flexible loop regions that contain several sequence motifs as an N-terminal myristoylation site, a central poly-proline PxxP motif for SH3 domain binding and C-terminal motifs for interaction with clathrin-associated endosomal adaptor protein complexes [11].

Although compounds interfering with Nef's activity would be in multiple ways beneficial to the host, Nef is currently not a target of antiviral measures. The Nef protein is not essential for replication of HIV in the infected host, yet the protein promotes the progression to AIDS in humans by the different internalization profiles found in SIV or HIV infected cells for CD3 and CD4 T cell receptors [12]. Previously described Nef-interacting small molecular compounds bind Nef only with relatively low affinity, and display high cytotoxicity and/or interfere with only a subset of Nef interactions and functions [13,14]. The characterization of a camelid single-domain antibody fragment, termed sdAb19, which binds to HIV-1 Nef with high affinity, has provided an alternative approach to inhibit the biological activities of Nef [15]. This 12.7 kDa antibody fragment interfered with the CD4 down-regulation activity of Nef, as well as with the association of Nef with Pak2 and the accompanying actin remodeling effects. In addition, sdAb19 was shown to counteract the Nef-dependent enhancement of virion infectivity and virus replication, and to be able to rescue Nef-mediated thymic CD4<sup>+</sup> T cell maturation defects in transgenic mice expressing Nef [15,16]. Here, we describe the crystal structure of the sdAb19 single domain antibody in complex with HIV-1 Nef<sub>SF2</sub> and an engineered SH3 domain of Hck. We provide structural and functional evidence for the potent inhibition of Nef caused by occupation of a highly conserved surface epitope at the C-terminus of Nef. These data represent important findings for the rational development of new antiviral strategies targeting HIV-1 Nef.

## Results


### Architecture of the Nef-sdAb19-SH3<sub>B6</sub> complex

The Nef-antibody complex was formed by mixing a purified recombinant form of HIV-1 Nef<sub>SF2</sub> (45–210) deleted of the first 44 N-terminal residues with sdAb19, and adding the SH3 domain of human Hck, termed SH3<sub>B6</sub> and engineered for high affinity binding to Nef, to this complex [17,18]. Analytical gel filtration showed

that addition of sdAb19 and SH3<sub>B6</sub> to Nef<sub>SF2</sub> led to formation of a stoichiometric 1:1:1 complex whose elution volume at an apparent mass of 45 kDa corresponded well to the calculated mass of 41.6 kDa (Figure 1A). To characterize the tripartite SH3<sub>B6</sub>-Nef-sdAb19 complex formation, we determined the individual binding affinities between Nef and its two complex partners by isothermal titration calorimetry (ITC). The two interacting domains, SH3<sub>B6</sub> and sdAb19, targeted Nef with similar individual affinities, showing dissociation constants of 19 nM and 39 nM, respectively, for binding to non-myristoylated Nef<sub>SF2</sub> (45–210) (Figure 1B,C). To explore if myristoylation of Nef affects binding to sdAb19, we used the lipidated protein and performed ITC measurements (Table 1). Myristoylated Nef was prepared by coexpression of full length Nef<sub>SF2</sub> with the N-myristoyl transferase and addition of myristic acid to the expression media [17]. The myristoylation reaction was confirmed by ESI mass spectrometry analysis (Additional file 1: Figure S1). However, Nef myristoylation showed no effect on the binding affinity to sdAb19 (Additional file 1: Figure S2A and Table 1). A similar result was observed previously for the binding of SH3<sub>B6</sub> to myrNef, which was not affected by the lipid modification of the viral protein [19].

The tripartite protein complex of HIV-1 Nef<sub>SF2</sub> (45–210, Δ158–178, deleted of the C-terminal flexible loop encompassing residues 158 to 178 of Nef<sub>SF2</sub>), human Hck-SH3<sub>B6</sub> (residues 79–138 of human Hck) and sdAb19 (residues 1–118) was purified by gel filtration and crystallized. The 2.1 Å structure was solved by molecular replacement using the Nef-SH3<sub>B6</sub> domain complex as a search model [19] (Materials and Methods, Additional file 1: Table S1). sdAb19 folds into a typical immunoglobulin domain closely resembling known llama single variable (V<sub>HH</sub>) structures [20–23]. The SH3<sub>B6</sub>-Nef-sdAb19 complex adopts an elongated shape and is formed between two subunits (chains A and B assigned to SH3<sub>B6</sub> and Nef, respectively) of one asymmetric unit cell with the antibody subunit from a symmetry mate unit cell (chain C' assigned to sdAb19) (Figure 1D). The Nef-sdAb19 interface covers an average molecular surface area of 718 Å<sup>2</sup>, whereas Nef-SH3<sub>B6</sub> covers an interface of 623 Å<sup>2</sup>, with no contacts formed between sdAb19 and SH3<sub>B6</sub>. This corresponds in total to 2,683 Å<sup>2</sup> buried molecular surface area on the three proteins upon assembly into the tripartite complex. The buried interface area of sdAb19 upon binding to Nef corresponds to 12% of the total solvent accessible area of the antibody. The two cysteines C24 and C97 of sdAb19, located in close proximity on opposing β-strands B and F, were found to be reduced and did not form an intramolecular disulfide bond in the crystal (Figure 1D and Additional file 1: Figure S3).

The camelid antibody was raised by immunization of the llama with recombinant Nef protein from the HIV-1



Lai allele, residues 57–205 [15]. To further characterize the sdAb19 binding specificity to different Nef alleles, we analyzed the commonly used NL4-3 and NA7 Nef proteins, which share a sequence identity of 85.7% and 89.0% with SF2 Nef, respectively. Whereas binding to Nef<sub>NL4-3</sub> was about 2-fold stronger compared to the SF2 allele, the dissociation constant of sdAb19 to Nef<sub>NA7</sub> was determined to 118 nM (Additional file 1: Figure S2B,C and Table 1). The binding affinity to NA7 Nef was thus 3-fold weaker than the affinity determined for sdAb19–Nef<sub>SF2</sub> complex formation. Four homologous replacements occur between NL4-3 and SF2 Nef proteins in the binding interface to sdAb19, including the notable alteration from M198 to valine [24]. Likewise, four changes are found between NA7 and SF2 Nef, of which the non-homologous change from proline at position 154 in Nef<sub>SF2</sub> to alanine in Nef<sub>NA7</sub> is the most prominent. Overall, these changes appear to be moderate as the affinity varies only six-fold from the tightest binding allele, NL4-3, compared to the weakest binding allele, NA7. Off note, all Nef residues in the binding interface to sdAb19 are completely identical between Bru/Lai Nef and NL4-3 Nef alleles. As the average sequence identity

of Nef proteins from all HIV-1 subgroups is 84% [25], the diversity of the three analyzed Nef alleles SF2, NL4-3 and NA7 represents typical variations from the consensus sequence observed in the nature.

The C-terminal flexible loop of Nef is required for cellular trafficking functions, as e.g. the internalization of CD4 molecules from the cell surface. Truncation of 21 residues within this C-terminal flexible loop of Nef<sub>SF2</sub> reduced the binding affinity to 98 nM suggesting a minor contribution of the flexible loop to the Nef–sdAb19 binding interaction (Additional file 1: Figure S2D). The thermodynamic parameters of the interactions and the binding stoichiometries are listed in Table 1.

#### Attenuation of sdAb19 binding by mutagenesis

sdAb19 targets Nef mainly by its three complementarity determining regions (CDRs) (Figure 2A). The buried surface area of Nef and sdAb19 involves 43 residues according to the PDBePISA survey ([www.ebi.ac.uk/msd-srv/prot\\_int/](http://www.ebi.ac.uk/msd-srv/prot_int/)) (Additional file 1: Figure S3). Of these, eleven residues in sdAb19 and eleven residues in Nef are contacting each other within a distance shell of 3.7 Å, indicating this surface patch as a conformational epitope

**Table 1 Thermodynamic parameters of isothermal titration calorimetry measurements**

Titration scheme <sup>a</sup>	$K_d$ (nM)	$\Delta G$ (kcal/mol)	$\Delta H$ (kcal/mol)	$\Delta S$ (kcal/mol/deg)	T $\Delta S$ (kcal/mol)	n ( $l^{-1}$ / $l_{-1}$ )
<b>a.) SH3<sub>B6</sub>-Nef-sdAb19 complex formation</b>						
SH3 <sub>B6</sub> to Nef <sub>SF2</sub> <sup>b</sup>	18.7	-10.55	-22.51 (±0.25)	-0.040	-11.96	0.81 (±0.005)
sdAb19 to Nef <sub>SF2</sub>	38.6	-10.11	-11.62 (±0.005)	-0.005	-1.51	0.81 (±0.002)
<b>b.) sdAb19 binding to Nef</b>						
sdAb19 to myrNef <sub>SF2</sub>	32.7	-10.20	-14.97 (±0.22)	-0.016	-4.77	0.81 (±0.006)
sdAb19 to Nef <sub>NL4-3</sub>	18.5	-10.37	-17.97 (±0.30)	-0.025	-7.42	0.88 (±0.007)
sdAb19 to Nef <sub>NA7</sub>	118	-9.45	-12.82 (±0.12)	-0.011	-3.34	0.74 (±0.004)
sdAb19 to Nef <sub>SF2</sub> ( $\Delta$ flex. loop)	98	-9.55	-10.71 (±0.06)	-0.004	-1.16	0.87 (±0.003)
<b>c.) sdAb19 mutant binding</b>						
sdAb19 (G102R,S103E) to Nef <sub>SF2</sub>	920	-8.25	-9.93 (±0.56)	-0.006	-1.68	0.9 (±0.085)
sdAb19 (D60R) to Nef <sub>SF2</sub>	3700	-7.40	-3.38 (±0.56)	0.014	4.02	0.74 (±0.009)
sdAb19 (triple) to Nef <sub>SF2</sub>	-	-	-	-	-	-
<b>d.) Nef<sub>SF2</sub> mutant binding</b>						
sdAb19 to Nef <sub>SF2</sub> (K148E)	1700	-7.86	-8.77 (±0.26)	-0.003	-0.89	0.74 (±0.015)
sdAb19 to Nef <sub>SF2</sub> (M198K)	-	-	-	-	-	-
sdAb19 to Nef <sub>SF2</sub> (L202K)	-	-	-	-	-	-
<b>e.) Neffin binding to Nef</b>						
Neffin to Nef <sub>SF2</sub>	1.6	-12.02	-38.26 (±0.17)	-0.088	-26.23	0.66 (±0.001)
Neffin to Nef <sub>NL4-3</sub>	3.9	-11.49	-33.19 (±0.20)	-0.073	-21.71	0.65 (±0.002)
Neffin to Nef <sub>NA7</sub>	14.4	-10.72	-34.69 (±0.12)	-0.080	-23.97	0.67 (±0.001)
Neffin (triple) to Nef <sub>SF2</sub>	23.3	-10.41	-18.13 (±0.12)	-0.026	-7.72	1.08 (±0.004)

<sup>a</sup>all ITC measurements were performed at 25°C.

<sup>b</sup>Recombinant Nef proteins refer to: Nef<sub>SF2</sub> (45–210, C59S, C210A); myrNef<sub>SF2</sub> (myr2-210, C59S, C210A); Nef<sub>NL4-3</sub> (41–206, C206A); Nef<sub>NA7</sub> (41–206, C206A).


for sdAb19. Core interacting residues form eight direct intermolecular hydrogen bonds and five salt bridges with only one water molecule buried in the binding interface (Figure 2B). Eight of the eleven directly interacting residues in sdAb19 are located in the CDRs (Figure 2C). Only one residue, N35, of the canonical CDR1 (residues 29–35 according to the definition by Chothia *et al.* [26]) contributes to the interaction, whereas the majority of contacts are mediated by residues located in CDR2 (residues 54–59). The non-canonical, hyper-variable CDR3 region (residues 100–107) instead appears rather short in sdAb19, and contributes only to a lesser extent to the interaction (Additional file 1: Figure S3).

To probe the interaction with Nef, we selected three residues in sdAb19 for site directed mutagenesis. The rationale for choosing these sites was based on their location within a complementarity determining region, and the amino acid changes were designed to maximally affect the interaction without impairing the solubility of the antibody. A key residue of sdAb19 in the complex interface is D60, whose side chain carboxylic group forms ionic interactions with K148 of Nef and a hydrogen bond to Y139 (Figure 2B,C). To explore the contribution

of D60 in binding to Nef, we mutated this residue to arginine, introducing thereby a charge reversal at this amino acid position while retaining the hydrophilic character of this surface residue. The dissociation constant of the sdAb19 D60R mutant for binding to Nef<sub>SF2</sub> was increased to 3.7  $\mu$ M as determined by ITC measurements, corresponding to a 100-fold weakening of the binding affinity (Figure 3A). In addition to this central residue, we chose two peripheral positions in sdAb19, G102 and S103, which were mutated to arginine and glutamic acid, respectively. This double mutation attenuated the binding affinity for Nef to 920 nM, corresponding to a 23-fold reduction compared to the native sdAb19 (Figure 3B). Only the combination of all three mutations, D60R/G102R/S103E, in sdAb19 finally led to a strong reduction in binding affinity, such that an interaction with Nef could no longer be detected by ITC (Figure 3C). These results showed that the binding capacity of sdAb19 to Nef can be experimentally scaled by introducing different substitutions into the key positions of this antibody fragment.

We tested the sdAb19 mutants in functional experiments for their effect on the Nef-mediated internalization of cell surface CD4. Whereas expression of Nef






**Figure 2** sdAb19 targets a C-terminal surface epitope on Nef. **(A)** Binding of sdAb19 to Nef<sub>SF2</sub>. The three complementarity determining regions are colored yellow (CDR1), red (CDR2), and blue (CDR3), respectively. **(B)** Residues of CDR2 are significantly involved in the interaction with Nef. Hydrogen bonds and salt bridges are displayed as dashed lines. **(C)** Interaction map of Nef and sdAb19 within a distance shell of 3.7 Å. Hydrophobic and polar interactions between main chain (dots) and side chain (bars) atoms are indicated by dashed lines colored grey and blue, respectively. For hydrogen bonds and salt bridges the inter-atomic distances are tabulated.

alone in CD4 expressing cells potentially stimulated the internalization of CD4 leading to only a residual 20% CD4 expression remaining at the cell surface (Figure 3D), co-expression of sdAb19 blocked this effect and restored surface CD4 expression to levels observed in the control cells. In contrast, this capacity to counteract the effect of Nef on CD4 downregulation was lost by the D60R sdAb19 mutant and the triple-mutant D60R/G102R/S103E, further establishing the critical role of these residues for the functionality of sdAb19.

#### sdAb19 targets a C-terminal surface epitope on HIV-1 Nef


The epitope on Nef that is recognized by sdAb19 encompasses a surface patch toward the C-terminus of the viral protein. A ring of charged residues, E155, R188, K148, K192, H196, E201 and H203, surrounds hydrophobic residues I137, V150, M198 and L202 at its center as well

as the polar Y139 and the adjacent G134 (Figure 4A). The binding interface delineated on the surface representation of HIV-1 Nef is shown in Figure 4B. This surface patch is conserved based on the analysis of 1643 alleles of HIV-1 Nef proteins from subtype B [24]. For ten residues of the sdAb19 binding interface the degree of sequence conservation is between 96% and 99.9%, based on the analysis of homologous amino acid replacements (Figure 4B). Only three residues, M198 (89.2%), L202 (77.5%), and I137 (62.2%), share a smaller degree of sequence conservation, with the isoleucine being mostly replaced by threonine. The high degree of sequence conservation of residues in the binding interface suggests that sdAb19 binds to almost all Nef alleles of the major HIV-1 subgroups in agreement with previous results showing that sdAb19 was able to inhibit a broad panel of Nef proteins from different HIV-1 groups [15].



Three different residues in Nef, namely K148, M198 and L202, were mutated to probe their contribution to the recognition by the antibody fragment. As the corresponding residue to D60 in sdAb19, lysine 148 in Nef was mutated to glutamate in order to break the salt bridge formation by charge reversal (Figure 4C). This

highly conserved lysine is in the center of a basic patch on Nef that forms the binding interface to sdAb19 as shown in the electrostatic surface display (Figure 4D). The dissociation constant for K148E increased to 1.7 μM as determined by ITC experiments, corresponding to a 44-fold weaker binding affinity compared to the




wild type Nef protein (Figure 4E). Interestingly, the two-fold difference in binding affinity of the sdAb19 mutant D60R ( $3.7 \mu M$ ) and the Nef mutant K148E ( $1.7 \mu M$ ) could result from the different length of the two charged residues, which leads to either exposure (D60R) or retraction (K148E) of the repulsive charge.

Mutation of either residue M198 or L202 in Nef to a large, basic lysine abrogated binding to sdAb19 in both cases (Additional file 1: Figure S4), underlining the importance of hydrophobic residues at these positions. These mutants however did not impair the ability of Nef to mediate CD4 internalization as shown when expressed

in CD4-positive cells (Additional file 1: Figure S5). This confirms on the one site the structural integrity of Nef upon these surface mutations. But it also suggests that residues M198 and L202 as part of the sdAb19 binding interface in Nef do not overlap with the CD4 binding surface of Nef. The inhibition of Nef-mediated down-regulation of CD4 by sdAb19 might instead occur at different sites of the large interaction surface between Nef and sdAb19. Together, these results show that sdAb19 binds to a C-terminal surface epitope of Nef that overlaps with distinct functions of the viral protein.

**Neffin (sdAb19–SH3<sub>B6</sub> fusion) forms a 2:2 complex with Nef**  
 We previously showed that fusion of sdAb19 to SH3<sub>B6</sub>, termed Neffin, markedly potentiated the binding affinity to HIV-1 Nef, and increased the efficacy of inhibition against all Nef functions in infected cells [16,27]. As

both protein domains bind to different surface patches of Nef, the covalent linkage combined the two individual binding affinities. A scheme of the domain assembly using three different linker lengths between 8 and 38 residues is shown in Figure 5A. Unexpectedly, size



**Figure 5 Neffin binding to Nef results in a 2:2 complex formation.** (A) Molecular architecture of the fusion of sdAb19 with SH3<sub>B6</sub> using a flexible linker of 8, 18, or 38 amino acid length. (B) Analytical gel filtration of Nef with sdAb19 and SH3<sub>B6</sub> or Neffin (8 aa linker) reveals a significant size increase for the Nef–Neffin complex. (C) Isothermal titration calorimetry confirms tight binding between Nef and Neffin exhibiting a  $K_D$  of 1.6 nM. (D) The triple mutation D60R/G102R/S103E in the sdAb19 subunit increased the dissociation constant of Neffin<sub>triple</sub> binding to Nef to the portion of the SH3<sub>B6</sub> domain alone as determined by ITC measurements. (E) The elution volume of the Nef–Neffin<sub>triple</sub> complex corresponds to an equimolar 1:1 binding stoichiometry due to the lack of sdAb19–Nef interaction.



exclusion chromatography revealed a significantly earlier elution volume for the Nef–Neffin complex compared to the tripartite SH3<sub>B6</sub>–Nef–sdAb19 complex generated from individual protein assembly (Figure 5B). This observation suggested the formation of a 2:2 Nef–Neffin complex. Variation of the linker length in Neffin up to 38 residues did not lead to formation of a 1:1 complex (Additional file 1: Figure S6), which might be explained by the opposite location of SH3 and sdAb19 binding surfaces on the structure of Nef. Of note, the very late retention of Neffin at an elution volume of 17 ml corresponds to the elution profile of the SH3 domain alone, confirming the building block construction strategy of this fusion protein. Using ITC experiments, the dissociation constant between Nef and Neffin was determined to 1.6 nM (Figure 5C). While the increase in avidity based on the accumulated strength of both subunits might not be as high as observed in other cases, e.g. compared to the 4,000-fold increase seen for the multivalent combination of two V<sub>HH</sub> fragments [28], it should be noted that the affinity determined by ITC is at the lower resolution limit of this technique. Surface plasmon resonance of the Nef<sub>NL4-3</sub>–Neffin interaction showed indeed binding in the picomolar affinity regime with very low dissociation rates [27].

To analyze the individual contributions of the two Neffin subunits to the complex formation with Nef, we introduced the sdAb19 triple mutation D60R/G102R/S103E to Neffin, named Neffin<sub>triple</sub>. This mutation reduced the binding affinity of Neffin<sub>triple</sub> to Nef to the contribution of the SH3<sub>B6</sub> domain alone (Figure 5D and Table 1), in line with the previous observation that the triple mutation in sdAb19 alone abrogated the interaction with Nef (Figure 3C). Size exclusion chromatography confirmed indeed formation of a 1:1 Nef–Neffin<sub>triple</sub> complex taking the expected higher hydrodynamic volume of the complex by the unbound sdAb19 subunit into account (Figure 5E).


Neffin<sub>triple</sub> as well as the Neffin D60R mutant were tested in functional experiments to study their contribution to the impairment of the Nef-induced CD4 internalization (Figure 6A). Whereas wild-type Neffin potently inhibited CD4 down-regulation by Nef, and fully restored CD4 surface expression levels for both NL4-3 and SF2 Nef alleles, the D60R mutant and the triple mutant failed to block CD4 down-regulation. This indicates that SH3 binding alone does not affect Nef's ability to interact with CD4 and connect it to the intracellular trafficking machinery, in line with previous observations [29]. Likewise, mutation of K148E, M198K or L202K in Nef, which strongly reduced binding to sdAb19, showed a gradually reduced susceptibility for the inhibition of CD4 internalization by wild-type Neffin (Figure 6B). These data indicate a reciprocal correlation between

sdAb19 binding and the ability of Nef to downregulate CD4. Nef(K148E), which was still able to bind sdAb19 but with a lower affinity (see Figure 4E), was functionally inhibited by Neffin only when high levels of Neffin were co-expressed at a 1:8 Nef:Neffin expression plasmid ratio. In contrast, the M198K and L202K mutants, which failed to display any affinity for sdAb19 (Additional file 1: Figure S4), were not or only poorly inhibited by Neffin even at the highest concentration (Figure 6B). Therefore, the formation of the 2:2 Nef–Neffin complex may lead to an additional coverage of Nef surfaces that would be otherwise accessible for interactions with host cell factors (Figure 6C). This effect might additionally contribute to the potency of Neffin for the inhibition of all HIV-1 Nef functions.

## Discussion

Here we define the structural basis of HIV-1 Nef inhibition by the camelid-derived sdAb19 antibody fragment. sdAb19 binds to a C-terminal surface epitope on Nef that overlaps with multiple interaction sites of the viral protein. Nef was shown to target the Pak2 serine/threonine kinase by a C-terminal sequence motif that involves K192 and F195 residues [30]. We find that K192 and H196 in Nef are directly interacting with sdAb19. These overlapping surface interaction sites may thus well explain how the interaction of Nef to Pak2 is impaired by the tight binding of sdAb19 [16], although other residues as the N-terminal VGF motif were shown to affect Pak2 binding as well [31].

The interaction with the cytoplasmic internalization motifs of CD4 and other T cell surface proteins has been mapped to a hydrophobic sorting motif recognition site between the two central helices in the core domain of Nef [32–34]. Although sdAb19 does not directly interact with residues of Nef that are supposed to mediate the interaction with CD4, its close proximity to the C-terminal flexible loop is likely involved in inhibition of this function. The C-terminal flexible loop of Nef harbors a di-leucine based sorting motif as well as flanking acidic motifs whose presence is required for Nef trafficking functions via contacts with the clathrin-associated adaptor protein machinery [35,11]. Deletion of the central 21 residues in the flexible loop of Nef reduced the binding affinity to sdAb19 by three-fold. As sdAb19 directly interacts with E155 in the flexible loop of Nef, this could affect the interaction of Nef with the endocytic machinery, thus inhibiting the downstream effects of Nef on cell surface receptor internalization. In line with this suggestion we previously showed that sdAb19 disrupted the direct interaction of Nef with endosomal adaptor protein complexes [16]. The antibody fragment however had no effect on the subcellular localization of Nef as previously shown [15]. This observation is in line with the finding that sdAb19 shows



**Figure 6 Binding of sdAb19 in Nefin correlates with the inhibition of CD4 internalization. (A)** HeLa-CD4 cells were transfected with plasmids for expression of either Nef-GFP or GFP in combination with the plasmid for expression of wild-type or mutated sdAb19 (1:3 Nef:sdAb19 plasmid ratio). Transfected cells were analyzed for CD4 cell surface expression and cell lysates were analyzed by Western blotting (inset panels) as in Figure 3D. **(B)** HeLa-CD4 cells were transfected with plasmids for expression of either Nef-GFP, mutant Nef-GFP or GFP alone (1:0 plasmid ratio) or in combination with increasing amounts of the plasmid for the expression of wild-type Nefin (1:4 or 1:8 plasmid ratio) and analyzed for CD4 cell surface expression. **(C)** Model of the complex formation between Nef and Nefin, consisting of the two individual Nef-binding domains sdAb19 and SH3<sub>B6</sub>. Formation of a stable 2:2 complex leads to coverage of additional surfaces in Nef that increases the inhibitory potential of Nefin against Nef functions.

similar binding affinities for an N-terminally truncated Nef 45–210 variant as well as the myristoylated full length protein. The data confirm that the myristate and the N-terminal polybasic patch that sustains membrane binding [36–39] are free to interact with lipid compartments even in the Nef–sdAb19 complex. These observations might explain the inhibition of all internalization stimulating functions of Nef by sdAb19 except for the downregulation of MHC-I, which supposedly does not occur at the plasma membrane [40]. This additional function is only abrogated through the coverage of the PxxP motif and flanking residues on the core domain of Nef by the SH3 domain moiety of Nefin [16].

The distinct 2:2 stoichiometry of the Nef–Nefin complex formation is surprising given that the two constituting domains, sdAb19 and SH3<sub>B6</sub>, bind Nef with similar affinities. While the topology of the interaction as seen from the structure determination clearly shows how

both molecules bind to opposing sites of Nef separated by a long distance, it is perhaps unexpected that we did not observe strings of Nef–Nefin assemblies, where high aggregates would form through alternating domain interactions. Such aggregation strings would occur if the second Nefin molecule binding to a preformed Nef–(sdAb19-SH3<sub>B6</sub>)–Nef complex would recruit a third Nef subunit into this complex. Instead, the sharp elution profile at a 2:2 molecular mass suggests the specific and very tight quaternary Nef–Nefin complex formation. It seems reasonable to propose that such an assembly could additionally contribute to the inhibitory function of Nefin, exceeding the combined effects of sdAb19 and SH3 alone, as additional surfaces of Nef might be covered through the 2:2 complex formation. A model regarding how a 2:2 Nef–Nefin complex assembly could lead to additional coverage of Nef surfaces is illustrated in Figure 6C.

## Conclusions

The structural and functional characterization of sdAb19 and Nefin binding to Nef opens a broad avenue for their rational usage. sdAb19 and Nefin can be used (i) for basic research as biochemical tools for in vitro analysis at the molecular and cellular level, where they could impair intracellular signaling and trafficking pathways mediated by Nef in infected cells. (ii) They can also be used for in vivo evaluation of inhibition of the dysregulatory effects of Nef on the immune system in a relevant animal model such as HIV-1 infected “humanized” mice. These latter experiments should also give definitive answer regarding validation of Nef as a rational target for development of new antiretroviral strategies. (iii) sdAb19 can be used as a tool for small chemical compound identification or lead compound optimization in high throughput assays or drug design approaches based on the structure of the Nef–sdAb19 complex. Through binding to the molecular area recognized by sdAb19, these compounds could mimic the inhibitory activity of sdAb19 on Nef functions. (iv) sdAb19 or Nefin might ultimately be directly used in HIV treatment through expression in infected cells either by gene transfer or after development of nano- and microparticle-based formulation strategies for efficient intracellular delivery. As both sdAb19 and Nefin proteins can be produced in high amounts in *E. coli*, their easy and low cost production and the possibility to tune their binding affinity to Nef from the sub-nanomolar to the high micromolar affinity range might facilitate a broad application in both academic and pharmaceutical research.

## Methods

### Plasmid cloning and protein production

Bacterial expression plasmids for HIV-1 Nef<sub>SF2</sub>, the SH3 domain of human Hck, and llama sdAb19 were described previously [19,27,41]. Expression and purification of full length myristoylated Nef<sub>SF2</sub> protein (myr2-210, C59S, C210A), an N-terminal deletion construct of Nef<sub>SF2</sub> (45–210, C59S, C210A), and a Nef<sub>SF2</sub> variant containing a deletion of the C-terminal flexible loop (45–210, Δ158–178, C59S, C210A) was performed similarly as described [17,41]. sdAb19 (1–118) was expressed as GST-fusion protein in *E. coli* and purified by affinity chromatography as described [27].

### Nef<sub>SF2</sub>–sdAb19–SH3<sub>B6</sub> crystallization

Initial screening for crystallization conditions of the Nef<sub>SF2</sub>–sdAb19–SH3<sub>B6</sub> complex was carried out using a Mosquito robot (TTP Labtech) with the sitting-drop method at 293 K and a concentration of 5–15 mg/ml. About 0.1 μl of protein solution was mixed with 0.1 μl of reservoir solution from a 70 μl reservoir in 96-well Hampton 3553 crystallization plates. Initial crystals of Nef<sub>SF2</sub>–sdAb19–SH3<sub>B6</sub> could be obtained in 0.2 M potassium

formate and 20% polyethylene glycol (PEG) 3350. Crystal conditions were optimized to 0.2 M potassium formate, 17.5% polyethylene glycol (PEG) 3350 and 0.35 M ammonium chloride grown by hanging-drop vapor diffusion in Linbro crystallization plates. Crystals grew under these conditions within 12 days to a size of 250 × 40 × 40 μm. For cryo-protection, crystals were transferred to a solution that contained the reservoir buffer with additional 25% ethylene glycol. After 5–10 seconds, crystals were flash-cooled in liquid nitrogen.

### Structure determination

The native diffraction data were measured from crystals cooled to cryogenic temperature of 100 K and were recorded on beamline X10SA (PXII) of the Swiss Light Source (SLS) equipped with an MAR 225 CCD detector (oscillation width per frame, 1°; 400 frames collected) to 2.1 Å resolution. The Nef<sub>SF2</sub>–sdAb19–SH3<sub>B6</sub> crystals were of space group P4<sub>1</sub> and had unit cell parameters of a = 73.07, b = 73.07 and c = 71.25 Å. Assuming the presence of one tripartite complex in the asymmetric unit, the solvent content of the crystals is 52.02%. The XDS package [42] was used to process, integrate, and scale the collected data. The structure was solved with molecular replacement using the Nef<sub>SF2</sub>–SH3<sub>B6</sub> (PDB entry 3RBB [19]) as a search model in PHASER [43]. The model was refined by alternating cycles of manual rebuilding in COOT [44] and minimization in REFMAC5 [45]. Data collection statistics and refinement parameters are given in Additional file 1: Table S1. Protein interfaces and accessible surface areas were calculated with the program PISA (<http://www.ebi.ac.uk/pdbe/>). Molecular diagrams were drawn using PyMOL (<http://www.pymol.org/>).

### Size exclusion chromatography

Analytical gel filtrations of recombinant Nef<sub>SF2</sub>, SH3<sub>B6</sub>, sdAb19, Nefin, and all mutants thereof were performed using a multicomponent Waters 626 LC system (Waters, MA) equipped with a Superdex S75 (10/300 GL) column (GE Healthcare). Typically, 100 μl of a 1.5 mg/ml protein solution was loaded onto the column that was equilibrated in 10 mM Tris/HCl (pH 9.0), 100 mM NaCl buffer prior to injection of the protein samples. Gel filtrations were run at a flow rate of 0.5 ml per minute in 10 mM Tris/HCl (pH 9.0), 100 mM NaCl onto the S75 column at 4°C or 20°C. The optical density was monitored at a wavelength of 280 nm over the time course of the experiment. Gel filtration experiments were performed repeated times.

### Isothermal titration calorimetry

Interaction of HIV-1 Nef<sub>SF2</sub> with SH3<sub>B6</sub>, sdAb19 or Nefin was performed by isothermal titration calorimetry using a MicroCal iTC200 microcalorimeter (GE Healthcare). Measurements were carried out in 20 mM Tris/HCl buffer

(pH 9.0), 100 mM NaCl at 25°C. SH3<sub>B6</sub>, sdAb19 or Nefin at a concentration of 200 μM were stepwise injected from the syringe to 20 μM Nef<sub>SF2</sub> placed in the measurement cell. The change in heating power was observed over the reaction time until equilibrium was reached. Data were analyzed using the software provided by the manufacturer.

### Cell culture, transfection, flow cytometry, and immunoblot analysis

Plasmids for expression in mammalian cells of wild-type Nef fused to the green fluorescent protein (Nef-GFP), as well as wild-type Myc-tagged forms of sdAb19 and Nefin, have been described previously [15,16]. Plasmids for expression of Nef, sdAb19 and Nefin mutants were constructed by PCR-mediated site-directed mutagenesis using specific primers and the wild-type expression vectors as templates. Cell culture experiments were performed in HeLa cells stably expressing CD4 similarly as described [15,16]. CD4 cell surface staining and flow cytometry analysis were performed as described previously [15]. Protein expression was analyzed on transfected cell lysates by Western blot using anti-c-Myc (9E10; Roche) or anti-GFP (sc-8334; Santa Cruz Biotechnology Inc.) antibodies [16].

### Accession numbers

The atomic coordinates and structure factors of the HIV-1 Nef<sub>SF2</sub>-Hck<sub>SH3-B6</sub>-sdAb19 complex have been deposited in the Protein Data Bank under accession code 4ORZ.

### Additional file

**Additional file 1: Table S1.** Data collection and refinement statistics of the SH3<sub>B6</sub>-Nef-sdAb19 crystal structure. **Figure S1.** Analytical characterization of HIV-1 Nef myristoylation. **Figure S2.** Isothermal titration calorimetry measurements of sdAb19 titrated to HIV-1 Nef proteins of different virus strains. **Figure S3.** Sequence and secondary structure display of the SH3<sub>B6</sub>-Nef<sub>SF2</sub>-sdAb19 complex structure. **Figure S4.** ITC measurements of sdAb19 titrated to Nef mutants. **Figure S5.** Cell surface down-regulation of CD4 is not changed by Nef mutations that affect sdAb19 binding. **Figure S6.** Size exclusion chromatography of Nefin constructs and complex formation with Nef. **Additional references.**

### Abbreviations

CDR: Complementarity determining region; GFP: Green fluorescent protein; HAART: Highly active anti-retroviral therapy; HIV: Human immunodeficiency virus; MFI: Mean fluorescence intensity; Nef: Negative factor; Nefin: Nef inhibitor; sdAb19: Single domain antibody 19; SIV: Simian immunodeficiency virus; TCR: T-cell receptor.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

SL purified proteins, performed binding studies, crystallized the protein complex and determined the crystal structure. JM and MCR performed cell surface expression experiments under the supervision of SB. AJ and KS contributed reagents and expertise. KS, SB and MG analyzed data. MG designed of the study and wrote the manuscript. All authors discussed the results and commented on the manuscript. All authors read and approved the final manuscript.

### Acknowledgements

We thank Karin Vogel-Bachmayr and Emilie Trinh for expert technical assistance and Dr. Ingrid Vetter for help with diffraction data analysis. This work was supported by grants from Inserm-Transfert and SATTidInnov to S.B.

### Author details

<sup>1</sup>Center of Advanced European Studies and Research, Group Physical Biochemistry, Bonn, Germany. <sup>2</sup>Department of Physical Biochemistry, Max Planck Institute of Molecular Physiology, Dortmund, Germany. <sup>3</sup>Inserm U1016, Institut Cochin, Paris, France. <sup>4</sup>CNRS, UMR8104, Paris, France. <sup>5</sup>Université Paris-Descartes, Sorbonne Paris-Cité, Paris, France. <sup>6</sup>Department of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland.

Received: 15 December 2013 Accepted: 4 March 2014

Published: 13 March 2014

### References

1. UNAIDS Report on the Global AIDS Epidemic. ; 2013. <http://www.unaids.org>.
2. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, Von Wyl V, Yerly S, Lima VD, Günthard HF, Gilks C, Pillay D: **Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.** *Lancet Infect Dis* 2009, **9**:409–417.
3. Flexner C: **HIV drug development: the next 25 years.** *Nat Rev Drug Discov* 2007, **6**:959–966.
4. Sigal A, Baltimore D: **As good as it gets? The problem of HIV persistence despite antiretroviral drugs.** *Cell Host Microbe* 2012, **12**:132–138.
5. Denton PW, Long JM, Wietgreffe SW, Sykes C, Spagnuolo RA, Snyder OD, Perkey K, Archin NM, Choudhary SK, Yang K, Hudgens MG, Pastan I, Haase AT, Kashuba AD, Berger EA, Margolis DM, Garcia JV: **Targeted cytotoxic therapy kills persisting HIV infected cells during ART.** *PLoS Pathog* 2014, **10**:e1003872.
6. West AP Jr, Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC: **Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy.** *Cell* 2014, **156**:633–648.
7. Malim MH, Emerman M: **HIV-1 accessory proteins—ensuring viral survival in a hostile environment.** *Cell Host Microbe* 2008, **3**:388–398.
8. Kirchhoff F: **Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses.** *Cell Host Microbe* 2010, **8**:55–67.
9. Kirchhoff F, Schindler M, Specht A, Arhel N, Münch J: **Role of Nef in primate lentiviral immunopathogenesis.** *Cell Mol Life Sci* 2008, **65**:2621–2636.
10. Foster JL, Garcia JV: **HIV-1 Nef: at the crossroads.** *Retrovirology* 2008, **5**:84.
11. Geyer M, Fackler OT, Peterlin BM: **Structure–function relationships in HIV-1 Nef.** *EMBO Rep* 2001, **2**:580–585.
12. Schindler M, Münch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Müller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques P, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F: **Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1.** *Cell* 2006, **125**:1055–1067.
13. Witkowski W, Verhasselt B: **Contributions of HIV-1 Nef to immune dysregulation in HIV-infected patients: a therapeutic target?** *Expert Opin Ther Targets* 2013, **17**:1345–1356.
14. Lülf S, Horenkamp FA, Breuer S, Geyer M: **Nef surfaces: where to interfere with function.** *Curr HIV Res* 2011, **9**:543–551.
15. Bouchet J, Basmaciogullari SE, Chrobak P, Stolp B, Bouchard N, Fackler OT, Chames P, Jolicœur P, Benichou S, Baty D: **Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody.** *Blood* 2011, **117**:3559–3568.
16. Bouchet J, Hérate C, Guenzel CA, Vérollet C, Järviuoma A, Mazzolini J, Rafie S, Chames P, Baty D, Saksela K, Niedergang F, Maridonneau-Parini I, Benichou S: **Single-Domain Antibody-SH3 Fusions for Efficient Neutralization of HIV-1 Nef Functions.** *J Virol* 2012, **86**:4856–4867.
17. Breuer S, Gerlach H, Kolaric B, Urbanke C, Opitz N, Geyer M: **Biochemical indication for myristoylation-dependent conformational changes in HIV-1 Nef.** *Biochemistry* 2006, **45**:2339–2349.
18. Hiiipakka M, Poikonen K, Saksela K: **SH3 domains with high affinity and engineered ligand specificities targeted to HIV-1 Nef.** *J Mol Biol* 1999, **293**:1097–1106.
19. Horenkamp FA, Breuer S, Schulte A, Lülf S, Weyand M, Saksela K, Geyer M: **Conformation of the Dileucine-Based Sorting Motif in HIV-1 Nef Revealed by Intermolecular Domain Assembly.** *Traffic* 2011, **12**:867–877.



20. Spinelli S, Frenken L, Bourgeois D, De Ron L, Bos W, Verrips T, Anguille C, Cambillau C, Tegoni M: **The crystal structure of a llama heavy chain variable domain.** *Nat Struct Biol* 1996, **3**:752–757.
21. Hinz A, Lutje Hulsik D, Forsman A, Koh WW, Belrhali H, Gorlani A, de Haard H, Weiss RA, Verrips T, Weissenhorn W: **Crystal structure of the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction.** *PLoS One* 2010, **5**:e10482.
22. Lutje Hulsik D, Liu YY, Strokappe NM, Battella S, El Khattabi M, McCoy LE, Sabin C, Hinz A, Hock M, Macheboeuf P, Bonvin AM, Langedijk JP, Davis D, Forsman Quigley A, Aasa-Chapman MM, Seaman MS, Ramos A, Poignard P, Favier A, Simorre JP, Weiss RA, Verrips CT, Weissenhorn W, Rutten L: **A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition.** *PLoS Pathog* 2013, **9**:e1003202.
23. Muyldermans S: **Nanobodies: natural single-domain antibodies.** *Annu Rev Biochem* 2013, **82**:775–797.
24. O'Neill E, Kuo LS, Krisko JF, Tomchick DR, Garcia JV, Foster JL: **Dynamic evolution of the human immunodeficiency virus type 1 pathogenic factor, Nef.** *J Virol* 2006, **80**:1311–1320.
25. Geyer M, Peterlin BM: **Domain assembly, surface accessibility and sequence conservation in full length HIV-1 Nef.** *FEBS Lett* 2001, **496**:91–95.
26. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G: **Structural repertoire of the human VH segments.** *J Mol Biol* 1992, **227**:799–817.
27. Järviuoma A, Strandin T, Lülf S, Bouchet J, Mäkelä AR, Geyer M, Benichou S, Saksela K: **High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain.** *PLoS One* 2012, **7**:e40331.
28. Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, De Haard HJ: **Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.** *PLoS One* 2011, **6**:e17665.
29. Fackler OT, Moris A, Tibroni N, Giese SI, Glass B, Schwartz O, Kräusslich HG: **Functional characterization of HIV-1 Nef mutants in the context of viral infection.** *Virology* 2006, **351**:322–339.
30. Agopian K, Wei BL, Garcia JV, Gabuzda D: **A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2.** *J Virol* 2006, **80**:3050–3061.
31. Meuwissen PJ, Stolp B, Iannucci V, Vermeire J, Naessens E, Saksela K, Geyer M, Vanham G, Arien KK, Fackler OT, Verhasselt B: **Identification of a highly conserved valine-glycine-phenylalanine amino acid triplet required for HIV-1 Nef function.** *Retrovirology* 2012, **9**:34.
32. Grzesiek S, Stahl SJ, Wingfield PT, Bax A: **The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef. Mapping of the Nef binding surface by NMR.** *Biochemistry* 1996, **35**:10256–10261.
33. Khalid M, Yu H, Sauter D, Usmani SM, Schmökel J, Feldman J, Gruters RA, van der Ende ME, Geyer M, Rowland-Jones S, Osterhaus AD, Kirchhoff F: **Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection.** *J Virol* 2012, **86**:4906–4920.
34. Schmökel J, Li H, Shabir A, Yu H, Geyer M, Silvestri G, Sodora DL, Hahn BH, Kirchhoff F: **Link between primate lentiviral coreceptor usage and Nef function.** *Cell Rep* 2013, **5**:997–1009.
35. Craig HM, Pandori MW, Guatelli JC: **Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity.** *Proc Natl Acad Sci USA* 1998, **95**:11229–11234.
36. Gerlach H, Laumann V, Martens S, Becker CF, Goody RS, Geyer M: **HIV-1 Nef membrane association depends on charge, curvature, composition and sequence.** *Nat Chem Biol* 2010, **6**:46–53.
37. Welker R, Harris M, Cardel B, Kräusslich HG: **Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity.** *J Virol* 1998, **72**:8833–8840.
38. Giese SI, Woerz I, Homann S, Tibroni N, Geyer M, Fackler OT: **Specific and distinct determinants mediate membrane binding and lipid raft incorporation of HIV-1(SF2) Nef.** *Virology* 2006, **355**:175–191.
39. Akgun B, Satija S, Nanda H, Pirrone GF, Shi X, Engen JR, Kent MS: **Conformational transition of membrane-associated terminally acylated HIV-1 Nef.** *Structure* 2013, **21**:1822–1833.
40. Roeth JF, Williams M, Kasper MR, Filzen TM, Collins KL: **HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail.** *J Cell Biol* 2004, **167**:903–913.
41. Breuer S, Schievink SI, Schulte A, Blankenfeldt W, Fackler OT, Geyer M: **Molecular design, functional characterization and structural basis of a protein inhibitor against the HIV-1 pathogenicity factor Nef.** *PLoS One* 2011, **6**:e20033.
42. Kabsch W: **Xds.** *Acta Crystallogr D Biol Crystallogr* 2010, **66**:125–132.
43. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ: **Phaser crystallographic software.** *J Appl Crystallogr* 2007, **40**:658–674.
44. Emsley P, Lohkamp B, Scott WG, Cowtan K: **Features and development of Coot.** *Acta Crystallogr D Biol Crystallogr* 2010, **66**:486–501.
45. Murshudov GN, Vagin AA, Dodson EJ: **Refinement of macromolecular structures by the maximum-likelihood method.** *Acta Crystallogr D Biol Crystallogr* 1997, **53**:240–255.

doi:10.1186/1742-4690-11-24

**Cite this article as:** Lülf *et al.*: Structural basis for the inhibition of HIV-1 Nef by a high-affinity binding single-domain antibody. *Retrovirology* 2014 **11**:24.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

